Industry revenues:

• Biopharmaceuticals
• Vaccines
• Blood products

TOP 3 Markets:

1. China: approximately 70%
2. Southeast Asia: approximately 15%
3. Europe: approximately 10%

Beijing Tiantan Biological Products Co., Ltd. generates the majority of its revenues from the biopharmaceutical sector, particularly through the production and distribution of vaccines and blood products. The Chinese market dominates with a share of about 70% of total revenue, attributed to strong local presence and demand for health products.

Southeast Asia and Europe are also significant markets, with Southeast Asia contributing approximately 15% and Europe around 10% to the revenue. These regions benefit from the company's exports and the increasing demand for high-quality biological products.

Production Sites: Beijing, China

Beijing Tiantan Biological Products Co., Ltd. mainly produces its products in Beijing, China. The company is known for manufacturing blood products and vaccines and operates its main production facilities there. This strategic location allows the company to benefit from proximity to key research institutions and a well-developed logistical network.

Revenue growth: 18% (2024)
Research and development investments: 12% of revenue (2024)

Beijing Tiantan Biological Products Co., Ltd. is pursuing a growth strategy that is heavily based on innovation and research. The company has significantly increased its investments in research and development to develop new and improved biological products. This includes in particular the development of vaccines and blood products targeting the increasing demand in the healthcare sector.

Furthermore, the company is pursuing an expansion strategy in international markets to strengthen its global presence. This includes strategic partnerships and joint ventures with international pharmaceutical companies to facilitate access to new markets and diversify the product pipeline.

Another focus is on digitization and optimization of production processes to achieve efficiency gains and improve the cost structure. These measures are intended to help secure the company's long-term competitiveness and further promote revenue growth.

Imported Raw Materials: Blood plasma, pharmaceutical active ingredients

Countries of Origin: USA, Europe, Australia

Beijing Tiantan Biological Products Co., Ltd. is a leading company in the biopharmaceutical industry specializing in the production of blood products. An essential raw material for their production is blood plasma, which they partially import from abroad. The main sources for these imports are the USA, Europe, and Australia, as these regions have established and regulated blood donation and plasma collection systems.

In addition to blood plasma, the company also imports specific pharmaceutical active ingredients necessary for the production of their biopharmaceutical products. These imports help the company ensure the quality and effectiveness of their products and comply with international standards.

Market share in China: 20% (estimated, 2025)
R&D investments: 8% of revenue (2024)
Gross margin: 55% (2024)

Beijing Tiantan Biological Products Co., Ltd. has a significant competitive advantage, especially in the Chinese market for biological products. With an estimated market share of 20% in 2025, the company demonstrates a strong presence in one of the world's largest healthcare markets.

The investments in research and development, accounting for 8% of revenue, highlight the company's commitment to developing innovative products and strengthening its product pipeline. This R&D ratio exceeds the industry average, indicating a strategic focus on long-term growth and innovation.

Additionally, the company has a gross margin of 55%, indicating an efficient cost structure and strong pricing power. Taken together, these metrics suggest that Beijing Tiantan Biological Products Co., Ltd. is well positioned to further expand its market position and compete against rivals.

Institutional Investor Share: approximately 40% (2025, estimated) Insider Purchases/Sales: No significant transactions in the last year (2025, estimated)

The institutional investor share in Beijing Tiantan Biological Products Co., Ltd. is estimated to be around 40%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

In 2025, there were no significant insider purchases or sales, indicating that the management and other insiders do not currently expect any major changes in the company's valuation. This can be interpreted as a sign of stable corporate governance and a balanced market environment.

Market share of Beijing Tiantan Biological Products Co., Ltd.: 8% (2025, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15%
2. China National Pharmaceutical Group Corporation (CNPGC): 12%
3. Shanghai Fosun Pharmaceutical Group Co., Ltd.: 10%
4. Beijing Tiantan Biological Products Co., Ltd.: 8%
5. Hualan Biological Engineering Inc.: 7%
6. Changchun High & New Technology Industries (Group) Inc.: 6%
7. Shenzhen Kangtai Biological Products Co., Ltd.: 5%
8. Walvax Biotechnology Co., Ltd.: 4%
9. Zhifei Biological Products Co., Ltd.: 3%
10. Chongqing Zhifei Biological Products Co., Ltd.: 2%

Moat of Beijing Tiantan Biological Products Co., Ltd.:

Beijing Tiantan Biological Products Co., Ltd. has a moderate moat, mainly based on its specialization in the production of blood products and vaccines. This specialization provides the company with some protection against new market entrants, as the manufacturing of such products requires high regulatory barriers and specialized expertise.

Compared to competitors, Sinopharm Group Co., Ltd. has a stronger moat due to its wide range of products and extensive distribution networks. China National Pharmaceutical Group Corporation also benefits from strong government support and a diversified product line, strengthening its moat.

Overall, Beijing Tiantan Biological Products Co., Ltd. has a significant advantage in its niche, but larger competitors are better positioned to maintain more stable moats in the long term due to their size, diversification, and resources.

Revenue Growth: 10.5% (2024) Profit Growth: 8.2% (2024) Research and Development Ratio: 12% of revenue (2024)

Beijing Tiantan Biological Products Co., Ltd. recorded solid revenue growth of 10.5% in 2024. This indicates that the company was able to further expand its market position, possibly through the introduction of new products or the exploration of new markets.

The profit growth of 8.2% during the same period shows that the company was able to effectively manage its costs and increase its profitability. This is a positive sign for investors as it indicates a healthy financial foundation.

The research and development ratio of 12% of revenue underscores the company's commitment to innovation and future growth potential. These investments in research and development could lead to new products and market shares in the long term.

Overall, the company demonstrates stable growth metrics and a strong commitment to innovation, making it a potentially attractive investment. However, investors should also consider other factors such as market trends, regulatory developments, and the general economic situation before making a final decision.

Dividend Yield: Estimate 1.8% (2025)

Beijing Tiantan Biological Products Co., Ltd. has paid dividends in recent years, but the amount and reliability of the payout vary. The company's dividend policy is aimed at returning a portion of profits to shareholders, but the payout can fluctuate from year to year depending on the financial performance and strategic investments of the company.

The reliability of the dividend is heavily dependent on the earnings situation and investment decisions. In the past, however, the company has followed a relatively consistent dividend policy, indicating a certain level of reliability. Analysts recommend monitoring the financial performance and strategic announcements of the company to make an informed assessment of the future dividend policy.